Review reveals SARS-CoV-2 biosynthetic enzymes as promising targets for drug repurposing, highlighting new pathways for direct-acting antiviral therapies.
The outbreak of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has raised a major global health concern. This urgent situation is pressing the world to respond with the development of novel vaccine or small molecule therapeutics for SARS-CoV-2. Drug repurposing screening is regarded as one of the most practical and rapid approaches for the discovery of such therapeutics. Direct-acting agents, targeting specific viral enzymes that play an essential role in viral replication, represent a milestone in antiviral therapy. Several biosynthetic enzymes of the SARS-CoV-2 were analyzed as potential targets to develop new therapeutic drugs. This work provides a basis and directions for future drug development and reuse on the protein level of COVID-19.
No takes yet. Share an insight, caveat, or question.
Castillo‐Garit et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: